Effects of continuous infusion of endothelin-1 in pregnant sheep.

Plasma concentration of endothelin-1, a potent vasoconstrictor produced by the vascular endothelium, has been observed to be significantly increased in a number of pathophysiological states, including preeclampsia. In the present study we have evaluated the effects of elevated plasma endothelin-1 in pregnant sheep by continuous exogenous endothelin-1 administration. Nine pregnant ewes (110+/-5 days' gestation) were instrumented for measurements of maternal mean arterial pressure, renal blood flow, and uterine blood flow. After recovery, endothelin-1 was infused intravenously for 4 hours at a dose that was adjusted to raise mean arterial pressure by approximately 20 mm Hg by the end of the first hour (range 5 to 20 ng/kg per minute). Mean arterial pressure, renal blood flow, uterine blood flow, urinary protein excretion, hematocrit, and plasma endothelin-1 concentration were measured hourly, and renal and uterine vascular resistances were calculated. Endothelin-1 produced significant increases (% change from baseline at t=4 hours) in mean arterial pressure (45+/-8%), renal vascular resistance (353+/-66 %), and uterine vascular resistance (59+/-21%). Endothelin-1 also increased microvascular permeability both systemically and within the kidney, as suggested by marked increases in hematocrit (0.27+/-0.01 to 0.32+/-0.01) and urinary protein concentration (0.95+/-0.1 to 7.9+/-3.2 mg/mL per mg creatinine). There was a highly significant correlation (P<.0001) between plasma endothelin-1 and mean arterial pressure, renal vascular resistance, uterine vascular resistance, hematocrit, and urinary protein content in all sheep studied. In addition, plasma endothelin-1 corresponded well with the time course of the changes in cardiovascular parameters and urinary protein excretion observed. These results provide evidence to suggest that elevation of circulating endothelin-1 in pregnant sheep can produce cardiovascular and hemodynamic changes that in many ways resemble the human disease preeclampsia. This supports the hypothesis that endothelial cell damage and/or dysfunction that is associated with increased production of endothelin-1 could directly contribute to the progression of preeclampsia.

[1]  J. López-Novoa,et al.  A role for platelet-activating factor in endothelin-1-induced rat mesangial cell proliferation. , 1993, European journal of pharmacology.

[2]  G. Remuzzi,et al.  Endothelins in the control of cardiovascular and renal function , 1993, The Lancet.

[3]  P. Chiu,et al.  Attenuation of ischemic acute renal failure by phosphoramidon in rats. , 1993, Pharmacology.

[4]  G. Remuzzi,et al.  A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. , 1993, Kidney international.

[5]  H. V. van Geijn,et al.  Endothelial vasoactive mediators in preeclampsia. , 1993, American journal of obstetrics and gynecology.

[6]  N. Perico,et al.  Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. , 1993, Kidney international.

[7]  K. Badr,et al.  Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. , 1992, The New England journal of medicine.

[8]  D. Yang,et al.  Effect of endothelin-1 on the uterine vasculature of the pregnant and estrogen-treated nonpregnant sheep. , 1992, American journal of obstetrics and gynecology.

[9]  J. Whitworth,et al.  The kidney in hypertensive pregnancies--victim and villain. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  A. Lerman,et al.  Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. , 1992, Journal of the American College of Cardiology.

[11]  N. Sjöberg,et al.  Contractile effect of endothelin in the human uterine artery and autoradiographic localization of its binding sites. , 1992, American journal of obstetrics and gynecology.

[12]  H. V. van Geijn,et al.  Endothelial function in normal and pre-eclamptic pregnancy: a hypothesis. , 1992, European journal of obstetrics, gynecology, and reproductive biology.

[13]  J. Roberts,et al.  Pathophysiology of preeclampsia. , 1991, Clinics in perinatology.

[14]  B. Sibai,et al.  The renin-angiotensin-aldosterone system in preeclampsia. A review. , 1991, Clinics in perinatology.

[15]  L. Myatt,et al.  Endothelin-1-induced vasoconstriction is not mediated by thromboxane release and action in the human fetal-placental circulation. , 1991 .

[16]  M. Sirois,et al.  Effects of endothelin‐1 on vascular permeability in the conscious rat: interactions with platelet‐activating factor , 1991, British journal of pharmacology.

[17]  M. Mitchell,et al.  Maternal plasma level of endothelin is increased in preeclampsia. , 1991, American journal of obstetrics and gynecology.

[18]  G. Dekker,et al.  Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe pre-eclampsia. , 1991, European journal of obstetrics, gynecology, and reproductive biology.

[19]  D. Gómez-Garre,et al.  Renal effects and mesangial cell contraction induced by endothelin are mediated by PAF. , 1991, Kidney international.

[20]  T. Lüscher,et al.  Endothelium-derived relaxing and contracting factors: perspectives in nephrology. , 1991, Kidney international.

[21]  J. Roberts,et al.  Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. , 1990, The Journal of clinical endocrinology and metabolism.

[22]  W. Henrich,et al.  Endothelial factors in the regulation of renin release. , 1990, Kidney international.

[23]  P. Braquet,et al.  Involvement of Endothelin in Renal Processes , 1990, Hypertension.

[24]  T. Musci,et al.  Preeclampsia: an endothelial cell disorder. , 1989, American journal of obstetrics and gynecology.

[25]  J. Belda,et al.  Outbreak of asthma associated with soybean dust. , 1989, The New England journal of medicine.

[26]  J. Roberts,et al.  Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. , 1988, American journal of obstetrics and gynecology.

[27]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[28]  J. Borm,et al.  Placental-type plasminogen activator inhibitor in preeclampsia. , 1988, American journal of obstetrics and gynecology.

[29]  R. Paul,et al.  Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. , 1985, The American journal of physiology.

[30]  B. Sibai,et al.  Biochemical corroboration of endothelial involvement in severe preeclampsia. , 1995, American journal of obstetrics and gynecology.

[31]  W. Trick,et al.  Therapeutic strategies in the prevention of acute renal failure. , 1994, Seminars in nephrology.

[32]  P. Kincaid‐smith,et al.  The kidney and hypertension in pregnancy , 1993 .

[33]  N. Perico,et al.  The possible role of endothelin in the process of progressive renal deterioration in experimental and human glomerulopathies. , 1993, Seminars in nephrology.

[34]  K. Takahashi,et al.  Endothelin in renal failure. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  M. Redfield,et al.  Integrated cardiac, renal, and endocrine actions of endothelin. , 1989, The Journal of clinical investigation.